The opinions are given by EMA's Committee for Medicinal Products for Human Use (CHMP) on the basis of recommendations by the Scientific Advice Working Party.
For more information and guidance on the qualification of novel methodologies, see Qualification of novel methodologies for medicine development.
Draft Qualification opinion for Centiloid measure of Amyloid PET to quantify brain amyloid deposition
English (EN) (262.72 KB - PDF)
Summary CL- Additional Analyses presented at Discussion Meeting for Centiloid measure of Amyloid PET to quantify brain amyloid deposition
English (EN) (201.19 KB - PDF)
Final briefing book submitted for qualification opinion on Centiloid measure of Amyloid PET to quantify brain amyloid deposition
English (EN) (3.7 MB - PDF)
Qualification Opinion for GFR slope as a Validated Surrogate Endpoint for RCT in CKD
English (EN) (278.75 KB - PDF)
Overview of comments on draft Qualification opinion for GFR slope as a Validated Surrogate Endpoint for RCT in CKD
English (EN) (306.66 KB - PDF)
DRAFT qualification opinion for GFR slope as a Surrogate Endpoint in RCT for CKD
English (EN) (283.21 KB - PDF)
Briefing document - GFR slope as a Surrogate Endpoint in RCT for CKD
English (EN) (5.73 MB - PDF)
Responses to list of issues - GFR slope as a Surrogate Endpoint in RCT for CKD
English (EN) (1.13 MB - PDF)
Presentation - GFR slope as a Validated Surrogate Endpoint for CKD in RCT
English (EN) (2.25 MB - PDF)
Qualification Opinion for Stride velocity 95th centile as primary endpoint in studies in ambulatory Duchenne Muscular Dystrophy studies
English (EN) (3.83 MB - PDF)
Overview of comments on draft Qualification Opinion for Stride velocity 95th centile as a primary endpoint in studies in ambulatory Duchenne Muscular Dystrophy
English (EN) (479.16 KB - PDF)
Draft Qualification Opinion for Stride velocity 95th centile as primary endpoint in studies in ambulatory Duchenne Muscular Dystrophy
English (EN) (3.88 MB - PDF)
Responses to list of issues - Stride velocity 95th centile as primary endpoint in studies in ambulatory Duchenne Muscular Dystrophy
English (EN) (1.2 MB - PDF)
Qualification opinion for the iBox Scoring System as a secondary efficacy endpoint in clinical trials investigating novel immunosuppressive medicines in kidney transplant patients
English (EN) (267.77 KB - PDF)
Overview of comments received on Draft Qualification Opinion of the iBox Scoring System as a secondary efficacy endpoint in clinical trials investigating novel immunosuppressive medicines in kidney transplant patients
English (EN) (92.13 KB - PDF)
DRAFT Qualification opinion for the iBox Scoring System as a secondary efficacy endpoint in clinical trials investigating novel immunosuppressive medicines in kidney transplant patients
English (EN) (395.33 KB - PDF)
Qualification opinion - Appendix for Final Draft Qualification Opinion
English (EN) (883.98 KB - PDF)
Qualification opinion - C-PATH response to iBox Scoring System (Composite Biomarker Panel) - Second List of Issues
English (EN) (978.7 KB - PDF)
Qualification opinion - C-PATH response to iBox Scoring System (Composite Biomarker Panel) - List of Issues
English (EN) (1.25 MB - PDF)
Qualification opinion - Applicant revised briefing book for iBox Scoring System (Composite Biomarker Panel)
English (EN) (4.9 MB - PDF)
Qualification opinion of the use of Enroll-HD (a Huntington’s disease patient registry) as a data source and infrastructure support for post-authorisation monitoring of medical products
English (EN) (451.18 KB - PDF)
Submission of comments on Enroll-HD: Registry for Huntington's Disease
English (EN) (250.47 KB - PDF)
Draft qualification opinion for the use of Enroll-HD (a Huntington’s disease patient registry) as a data source and infrastructure support for post-authorisation monitoring of medical products
English (EN) (357.31 KB - PDF)
Enroll-HD Registry for Huntington's Disease - Briefing Package - 1 of 2 - questions and answers and context of use
English (EN) (288.25 KB - PDF)
Enroll-HD Registry for Huntington's Disease - Briefing package - 2 of 2 - Supplement
English (EN) (192 KB - PDF)
Qualification Advice List of Issues: Enroll-HD Response
English (EN) (2.13 MB - PDF)
Qualification opinion for Prognostic Covariate Adjustment (PROCOVA™)
English (EN) (518.38 KB - PDF)
Overview of comments received for Prognostic Covariate Adjustment (PROCOVA™) with responses
English (EN) (550.78 KB - PDF)
Draft qualification opinion for prognostic covariate adjustment (PROCOVA™)
English (EN) (502.62 KB - PDF)
Briefing book
English (EN) (646.89 KB - PDF)
PROCOVA™ handbook
English (EN) (276.87 KB - PDF)
Response to list of issues
English (EN) (280.04 KB - PDF)
Response to 2nd list of issues
English (EN) (315.15 KB - PDF)
Qualification Opinion of Islet Autoantibodies (AAs) as Enrichment Biomarkers for Type 1 Diabetes (T1D) Prevention Clinical Trials
English (EN) (1.88 MB - PDF)
Overview of comments received on Draft qualification opinion on Islet Autoantibodies (AAs) with answers
English (EN) (171.28 KB - PDF)
Draft qualification opinion of Islet Autoantibodies (AAs) as Enrichment Biomarkers for Type 1 Diabetes (T1D) Prevention Clinical Trials
English (EN) (1.87 MB - PDF)
Islet Autoantibodies (AAs) - Briefing document
English (EN) (1.97 MB - PDF)
Islet Autoantibodies (AAs) - Written response to the list of issues
English (EN) (585.28 KB - PDF)
Islet Autoantibodies (AAs) - Appendix H
English (EN) (8.45 MB - PDF)
Qualification opinion on IMI PREFER
English (EN) (349.74 KB - PDF)
Overview of comments received on draft qualification opinion on IMI PREFER
English (EN) (548.86 KB - PDF)
Draft qualification opinion on IMI PREFER
In this follow-up procedure to a previous qualification advice, IMI PREFER seek qualification for a framework (see documents in Annex provided by the applicant for qualification opinion by the CHMP) intended to provide suggestions on how patients’ perspectives could be measured through patient 11 preference studies and then incorporated into regulatory decision processes, as applicable.
Relevant considerations include what matters to patients, how much it matters, and how e.g., trade-offs between benefits and harms as well as other study object attributes of interest can be identified and 14 addressed from the patients’ perspective.
English (EN) (356.51 KB - PDF)
CHMP & EUnetHTA parallel Scientific Advice: Qualification of a Framework & Points to consider for method selection with methods for performing patient preference studies to inform regulatory & HTAbody medical product decision-making: Briefing document
English (EN) (3.37 MB - PDF)
Qualification opinion on Multiple sclerosis clinical outcome assessment (MSCOA)
English (EN) (1.27 MB - PDF)
Overview of comments received on 'Draft qualification opinion on Multiple Sclerosis Clinical Outcome Assessment (MSCOA) qualification opinion'
English (EN) (648.88 KB - PDF)
Draft qualification opinion of Multiple sclerosis clinical outcome assessment (MSCOA)
English (EN) (1.08 MB - PDF)
Qualification opinion of clinically interpretable treatment effect measures based on recurrent event endpoints that allow for efficient statistical analyses
English (EN) (1.38 MB - PDF)
Overview of comments on the draft qualification opinion of clinically interpretable treatment effect measures based on recurrent event endpoints that allow for efficient statistical analyses
English (EN) (579.82 KB - PDF)
Draft qualification opinion of clinically interpretable treatment effect measures based on recurrent event endpoints that allow for efficient statistical analyses
English (EN) (820.73 KB - PDF)
Qualification opinion - Treatment effect measures when using recurrent event endpoints - Applicant's submission
English (EN) (887.79 KB - PDF)
Qualification opinion - Treatment effect measures when using recurrent event endpoints - First list of issues
English (EN) (230.69 KB - PDF)
Qualification opinion - Treatment effect measures when using recurrent event endpoints - Applicant's responses to first list of issues
English (EN) (926.41 KB - PDF)
Qualification opinion - Treatment effect measures when using recurrent event endpoints - Second list of issues
English (EN) (635.97 KB - PDF)
Qualification opinion - Treatment effect measures when using recurrent event endpoints - Applicant's responses to second list of issues
English (EN) (1.49 MB - PDF)
Qualification opinion - Treatment effect measures when using recurrent event endpoints - Third list of issues
English (EN) (61.41 KB - PDF)
Qualification opinion - Treatment effect measures when using recurrent event endpoints - Applicant's responses to third list of issues
English (EN) (1.4 MB - PDF)
Qualification opinion - Treatment effect measures when using recurrent event endpoints - Fourth list of issues
English (EN) (60.18 KB - PDF)
Qualification opinion - Treatment effect measures when using recurrent event endpoints - Applicant's responses to fourth list of issues
English (EN) (603.62 KB - PDF)
Qualification opinion on eSource Direct Data Capture (DDC)
English (EN) (1.23 MB - PDF)
Overview of comments on the draft qualification opinion on eSource Direct Data Capture (DDC)
English (EN) (785.42 KB - PDF)
Draft qualification opinion on eSource Direct Data Capture (DDC)
English (EN) (415.85 KB - PDF)
Qualification opinion on stride velocity 95th centile as a secondary endpoint in Duchenne Muscular Dystrophy measured by a valid and suitable wearable device
English (EN) (2.72 MB - PDF)
Overview of comments on 'Stride velocity 95th centile as a secondary endpoint in Duchenne Muscular Dystrophy measured by a valid and suitable wearable device' (EMA/532515/2018)
English (EN) (316.92 KB - PDF)
Draft qualification opinion on stride velocity 95th centile as a secondary endpoint in Duchenne Muscular Dystrophy measured by a valid and suitable wearable device
This report provides a final agreed draft Context of Use for public consultation describing where Stride Velocity measured at the ankle 95th Centile is deemed by CHMP as an appropriate endpoint in studies to support regulatory decision making on medicines for the treatment of Duchenne Muscular Dystrophy (DMD), together with CHMP's scientific consideration of the submission leading to the draft opinion. The document also includes the questions posed by the applicant and also raised by CHMP to the Applicant, and all the data provided by the applicant in support of the Application.
English (EN) (2.49 MB - PDF)
Qualification opinion on Cellular therapy module of the European Society for Blood & Marrow Transplantation (EBMT) Registry
English (EN) (584.25 KB - PDF)
Overview of comments received on 'Draft qualification opinion on Cellular therapy module of the European Society for Blood & Marrow Transplantation (EBMT) Registry' (EMA/CHMP/SAWP/423488/2018)
English (EN) (498.42 KB - PDF)
Draft qualification opinion on Cellular therapy module of the European Society for Blood & Marrow Transplantation (EBMT) Registry
English (EN) (693.58 KB - PDF)
Qualification Opinion on The European Cystic Fibrosis Society Patient Registry (ECFSPR) and CF Pharmaco-epidemiology Studies
English (EN) (1.1 MB - PDF)
Review of comments submitted on the draft Qualification opinion - The European Cystic Fibrosis Society Patient Registry (ECFSPR)
English (EN) (195.58 KB - PDF)
Qualification opinion - The European Cystic Fibrosis Society Patient Registry (ECFSPR)
This report provides a draft context of use for public consultation describing where this registry is deemed by CHMP as an appropriate data source for post-authorisation studies to support regulatory decision making on medicines for the treatment of cystic fibrosis, together with CHMP's response to the questions posed by the Consortium.
English (EN) (875.42 KB - PDF)
Qualification opinion on dopamine transporter imaging as an enrichment biomarker for Parkinson’s disease clinical trials in patients with early Parkinsonian symptoms
Critical Path Global Ltd.’s Critical Path for Parkinson’s (CPP) is a multinational consortium of the Critical Path Institute supported by Parkinson’s UK and industry. This broad collaboration of pharmaceutical companies, government agencies, academic institutions, and charities aims to accelerate the development of therapies for Parkinson’s disease (PD).
English (EN) (762.14 KB - PDF)
Overview of comments on 'Draft qualification opinion on molecular neuroimaging of the dopamine transporter as biomarker to identify patients with early manifest Parkinsonism in Parkinson’s disease'
Submission of comments on 'Draft qualification opinion on molecular neuroimaging of the dopamine transporter as biomarker to identify patients with early manifest Parkinsonism in Parkinson’s disease' (EMA/765041/2017)
English (EN) (297.59 KB - PDF)
Draft qualification opinion on molecular neuroimaging of the dopamine transporter as biomarker to identify patients with early manifest Parkinsonism in Parkinson’s disease
Qualification of molecular neuroimaging of the dopamine transporter as biomarker for to identify patients with early manifest Parkinsonism in Parkinson’s disease.
English (EN) (723.8 KB - PDF)
Qualification opinion on plasma fibrinogen as a prognostic biomarker (drug development tool) for all-cause mortality and COPD exacerbations in COPD subjects
English (EN) (293.22 KB - PDF)
Overview of comments on 'Draft qualification opinion on plasma fibrinogen as a prognostic biomarker (drug development tool) for all-cause mortality and COPD exacerbations in COPD subjects'
English (EN) (76.34 KB - PDF)
Draft qualification opinion on plasma fibrinogen as a prognostic biomarker (drug development tool) for all-cause mortality and COPD exacerbations in COPD subjects
The COPD Foundation, COPD Biomarker Qualification Consortium (CBQC) has presented the background information, proposed contexts of use, and data analyses to support their proposal for the qualification of plasma fibrinogen as a drug development tool (prognostic biomarker) to identify COPD subjects at high risk for all-cause mortality or COPD exacerbations for inclusion in interventional clinical trials. The intent is to enable trials which utilize these important endpoints to be conducted more efficiently (reduced subject numbers, reduced study costs) by study sponsors with improved confidence in the study outcomes.
English (EN) (330.04 KB - PDF)
Qualification opinion on Proactive in chronic obstructive pulmonary disease (COPD)
English (EN) (969.1 KB - PDF)
Overview of comments received on "Qualification opinion on Proactive in chronic obstructive pulmonary disease (COPD)"
English (EN) (80.41 KB - PDF)
Draft qualification opinion on Proactive in chronic obstructive pulmonary disease (COPD)
Under the Innovative Medicines Initiative Joint-Undertaking (IMI-JU) framework, the public-private PROactive Consortium developed two Patient Reported Outcome (PRO) instruments to capture physical activity (PA) data in patients with Chronic Obstructive Pulmonary Disease (COPD) in clinical trial settings. One of those tools is the D-PPAC which is supposed to enable daily data collection (recall period of 1 day).
English (EN) (1011.85 KB - PDF)
Qualification opinion on paediatric ulcerative colitis activity index (PUCAI)
This is a non-invasive clinical disease activity multi-item index aimed to reflect the severity of ulcerative colitis (UC) in children. It is aimed to be discriminative (i.e. evaluating disease activity for judging study entry) and evaluative (as an outcome measure in paediatric UC with and without endoscopic assessment).
English (EN) (145.52 KB - PDF)
Overview of comments received on 'Qualification opinion on paediatric ulcerative colitis activity index (PUCAI)'
Comments on 'Qualification Opinion of paediatric ulcerative colitis activity index (EMA/CHMP/SAWP/485560/2015)
English (EN) (110.72 KB - PDF)
Draft qualification opinion on the paediatric ulcerative colitis activity index (PUCAI)
The paediatric ulcerative colitis activity index (PUCAI) measures disease activity in pediatric ulcerative colitis (Turner D. et al., 2007). It was developed to act as an accurate non-invasive (i.e. suitable for children) reflection of endoscopic inflammatory activity and has proven to have high reliability and responsiveness to change in clinical trials. After its publication, it has also proved to be highly accurate in predicting clinical course of pediatric ulcerative colitis and hence was incorporated in international clinical algorithms for the management of acute severe ulcerative colitis and ambulatory pediatric ulcerative colitis.
English (EN) (149.37 KB - PDF)
Qualification opinion on ingestible sensor system for medication adherence as biomarker for measuring patient adherence to medication in clinical trials
Proteus® Digital Health™ Inc. (Proteus) has developed an ingestible event marker (IEM, also known as
ingestible sensor (IS)), a platform technology that can be co-formulated with active pharmaceutical
compounds into drug/device combinations, integrating measuring of medication adherence into oral
pharmacotherapy.
English (EN) (1.08 MB - PDF)
Draft qualification opinion on the ingestible sensor system for medication adherence as biomarker for measuring patient adherence to medication in clinical trials
Proteus Digital Health Inc. intends to have its Proteus technology approved as a ‘qualified method’ for measuring adherence to medication in clinical trials by associating relevant physiologic and behavioural parameters, such as indications of therapeutic response. The Proteus technology is an ingestible event marker, a platform technology that can be co-formulated with active pharmaceutical compounds into drug/device combinations, integrating measuring of medication adherence into oral pharmacotherapy. The ingestible event marker is approved for marketing in the European Union and the United States as a medical device.
English (EN) (1.26 MB - PDF)
Qualification opinion - Total Kidney Volume (TKV) as a prognostic biomarker for use in clinical trials evaluating patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
English (EN) (427.25 KB - PDF)
Overview of comments on 'Total kidney volume (TKV) as a prognostic biomarker for use in clinical trials evaluating patients with autosomal dominant polycystic kidney disease (ADPKD)'
English (EN) (89.44 KB - PDF)
Draft qualification opinion total kidney volume (TKV) as a prognostic biomarker for use in clinical trials evaluating patients with autosomal dominant polycystic kidney disease (ADPKD)
The Critical Path Institute’s Polycystic Kidney Disease Outcome Consortium (PKDOC) intends to qualify Total Kidney Volume (TKV) as a prognostic biomarker (i.e. predictive for the outcome with the current standard of treatment) in order to improve efficiency in conducting clinical trials. The applicant started to work with the United States Food and Drug Administration in 2010 and initiated the discussion with the European Medicines Agency in 2013. Five observational studies including long-term outcome regarding the change in TKV over time, with or without various therapeutic interventions (such as diet, blood pressure control, cytostatics etc.) have been integrated into one database according to Clinical Data Interchange Standards Consortium (CDISC) standards.
English (EN) (425.29 KB - PDF)
Presentation - PKD presentation of outcomes: Consortium / European Medicines Agency Scientific Advice Working Party teleconference (Third list of issues)
Presentation of PKD outcomes consortium European Medicines Agency Scientific Advice Working Party teleconference (3rd List of issues)
English (EN) (576.73 KB - PDF)
Final briefing book - Qualification of total kidney volume as a prognostic biomarker for use in clinical trials evaluating patients with autosomal dominant polycystic kidney disease (ADPKD)
English (EN) (4.5 MB - PDF)
PKDOC response to the European Medicines Agency third list of issues - Total kidney volume as a prognostic biomarker for use in clinical trials evaluating patients with autosomal dominant polycystic kidney disease (ADPKD...
English (EN) (904.91 KB - PDF)
Qualification opinion list of issues - Total kidney volume (TKV) as a prognostic biomarker for use in clinical trials evaluating patients with autosomal dominant polycystic kidney disease (ADPKD)
English (EN) (210.16 KB - PDF)
Draft qualification opinion of qualification of exacerbations of chronic pulmonary disease tool (EXACT), and EXACT-respiratory symptoms measure (E-RS) for evaluating treatment outcomes in clinical trials in chronic pulmo...
The EXACT-PRO Initiative (EXAcerbations of Chronic Pulmonary Disease Tool – Patient-Reported Outcome) brought together clinical, research, methodology, and regulatory experts to develop a new patient-reported outcome (PRO) instrument to standardize the symptomatic assessment of exacerbations of COPD for evaluating frequency, severity, and duration of exacerbations in clinical trials of COPD (“EXACT”, 14-items PRO).
English (EN) (739.37 KB - PDF)
User manual E-RS (EXACT-respiratory symptoms): Applicant submission version 3.0
English (EN) (1.17 MB - PDF)
User manual (EXACT): Applicant submission version 7.0
English (EN) (2 MB - PDF)
Qualification opinion on in-vitro hollow-fibre-system model of tuberculosis (HFS-TB)
The CPTR initiative is a broad collaboration of pharmaceutical companies, government regulatory and multilateral agencies, academia, civil society advocates and non-government organizations that aim to accelerate the development of new, safe and highly effective TB treatment regimens with shorter therapy durations than the current standard of care. CPTR was formed through the collaboration and support of the Bill & Melinda Gates Foundation, the Global Alliance for TB Drug Development and the Critical Path Institute. The CPTR PCS-WG strives to identify, develop consensus around and build the evidence base to support potential new drug development tools (DDTs) for TB medical product development.
English (EN) (301.42 KB - PDF)
Draft qualification opinion on in vitro hollow-fibre-system model of tuberculosis (HFS-TB)
Approximately 10 years ago, the HFS-TB was developed by Gumbo et al. and first presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Since that time, the model has been refined to become more sophisticated in its utility and application, which has expanded to include the ability to influence effective dose selection in clinical settings. The HFS-TB enables a quantitative understanding of the relationship between dynamic drug concentrations, as well as dynamic populations of drug-susceptible and drug-resistant Mycobacterium tuberculosis, over time.
English (EN) (315.39 KB - PDF)
Response to the European Medicines Agency list of issues - In vitro hollow-fibre-system model of tuberculosis (HFS-TB)
English (EN) (344.83 KB - PDF)
Dossier submitted for qualification opinion - In vitro hollow-fibre-system model of tuberculosis (HFS-TB)
English (EN) (757.04 KB - PDF)
Presentation for Drug Regimens Consortium (CPTR) scientific-advice meeting with the European Medicines Agency: Hollow-fiber system for tuberculosis (HFS-TB)
English (EN) (887.43 KB - PDF)
Qualification opinion of MCP-Mod as an efficient statistical methodology for model-based design and analysis of phase-II dose-finding studies under model uncertainty
English (EN) (228.82 KB - PDF)
Overview of comments on the qualification opinion of MCP-Mod as an efficient statistical methodology for model-based design and analysis of Phase II dose finding studies under model uncertainty'
English (EN) (334.49 KB - PDF)
Request for CHMP Qualification Opinion - Annex 1
English (EN) (1.06 MB - PDF)
Request for CHMP qualification opinion response to questions dated 11 June 2013 - Annex 2
English (EN) (404.71 KB - PDF)
Discussion meeting for MCP-Mod qualification opinion request - Annex 3
English (EN) (745.39 KB - PDF)
Draft qualification opinion of MCP-Mod as an efficient statistical methodology for model-based design and analysis of phase-II dose-finding studies under model uncertainty
Estimating dose-response and selection of a dose for confirmatory Phase III trials and potential market
authorisation is among the most difficult elements of the whole development process. Dose finding
studies are commonly designed using a small number of doses and a narrow dose-range, often focused
on the upper end of the dose response relationship.
English (EN) (400.47 KB - PDF)
Request for CHMP qualification opinion on efficient statistical methodology for model-based design and analysis of phase-II dose-finding studies under model uncertainty
English (EN) (1.06 MB - PDF)
Response to the questions raised by the qualification team - CHMP qualification opinion on efficient statistical methodology for model-based design and analysis of phase-II dose-finding studies under model uncertainty
English (EN) (404.71 KB - PDF)
Presentation for discussion meeting on efficient statistical methodology for model-based design and analysis of phase-II dose-finding studies under model uncertainty
English (EN) (745.39 KB - PDF)
Qualification opinion of a novel data-driven model of disease progression and trial evaluation in mild and moderate Alzheimer’s disease
English (EN) (1.57 MB - PDF)
Overview of comments on 'qualification opinion of a novel data-driven model of disease progression and trial evaluation in mild and moderate Alzheimer’s disease'
English (EN) (79.55 KB - PDF)
Draft qualification opinion of a novel data-driven model of disease progression and trial evaluation in mild and moderate Alzheimer’s disease
The work described in this submission is intended to produce a tool that provides a common quantitative basis for the evaluation of study design and analysis methodologies for clinical studies in the mild and moderate Alzheimer's-disease population, with cognition as a primary endpoint.
English (EN) (1.6 MB - PDF)
Qualification opinion of Alzheimer’s disease novel methodologies / biomarkers for the use of cerebrospinal-fluid amyloid beta 1-42 and t-tau and / or positron-emission-tomography amyloid imaging (positive / negative) as ...
The European Medicines Agency’s (EMA) qualification process is a new, voluntary, scientific pathway leading to either a CHMP opinion or a Scientific Advice of novel methodologies on innovative methods or drug development tools.
English (EN) (565.94 KB - PDF)
Overview of comments received on 'qualification opinion of Alzheimer’s disease novel methodologies / biomarkers for the use of cerebrospinal-fluid amyloid beta 1-42 and t-tau and / or positron-emission-tomography amyloid...
English (EN) (134.24 KB - PDF)
Qualification opinion of Alzheimer’s disease novel methodologies / biomarkers for the use of cerebrospinal-fluid amyloid beta 1-42 and t-tau signature and / or positron-emission-tomography amyloid imaging (positive / neg...
In follow-up to the positive qualification opinion on the use of cerebrospinal fluid (CSF) biomarkers in predementia Alzheimer's disease adopted on 14 April 2011 (EMA/CHMP/SAWP/102001/2011).
English (EN) (521.1 KB - PDF)
Qualification opinion of Alzheimer’s disease novel methodologies / biomarkers for positron-emission-tomography amyloid imaging (positive / negative) as a biomarker for enrichment, for use in regulatory clinical trials in...
The European Medicines Agency’s (EMA) qualification process is a new, voluntary, scientific pathway leading to either a CHMP opinion or a Scientific Advice of novel methodologies on innovative methods or drug development tools.
English (EN) (369.23 KB - PDF)
Overview of comments received on 'qualification opinion of Alzheimer’s disease novel methodologies / biomarkers for positron-emission-tomography amyloid imaging (positive / negative) as a biomarker for enrichment, for us...
English (EN) (142.14 KB - PDF)
Qualification opinion of Alzheimer’s disease novel methodologies / biomarkers for positron-emission-tomograpy amyloid imaging (positive / negative) as a biomarker for enrichment for use in predementia Alzheimer's disease...
In follow-up to the positive qualification opinion on the use of cerebrospinal fluid (CSF) biomarkers in predementia Alzheimer's disease adopted on 14 April 2011 (EMA/CHMP/SAWP/102001/2011).
English (EN) (281.54 KB - PDF)
Qualification opinion of low hippocampal volume (atrophy) by magnetic-resonance imaging for use in clinical trials for regulatory purpose in predementia stage of Alzheimer’s disease
The European Medicines Agency’s (EMA) qualification process is a new, voluntary, scientific pathway leading to either a CHMP opinion or a Scientific Advice of novel methodologies on innovative methods or drug development tools. It includes qualification of biomarkers developed by consortia, networks, public/private partnerships, learned societies or pharmaceutical industry for a specific intended use in pharmaceutical research and development.
English (EN) (664.89 KB - PDF)
Overview of comments on 'qualification opinion of low hippocampal volume (atrophy) by magnetic-resonance imaging for use in clinical trials for regulatory purpose in predementia stage of Alzheimer’s disease'
English (EN) (164.88 KB - PDF)
Qualification opinion of low hippocampal volume (atrophy) by magnetic-resonance imaging for use in regulatory clinical trials in predementia stage of Alzheimer’s disease
English (EN) (700.84 KB - PDF)
Qualification opinion of novel methodologies in the predementia stage of Alzheimer’s disease: cerebrospinal-fluid-related biomarkers for drugs affecting amyloid burden
English (EN) (418.09 KB - PDF)
Overview of comments received on 'qualification opinion of novel methodologies in the predementia stage of Alzheimer’s disease: cerebrospinal-fluid-related biomarkers for drugs affecting amyloid burden'
English (EN) (351.91 KB - PDF)
Qualification opinion of Alzheimer’s disease novel methodologies / biomarkers for BMS-708163
English (EN) (183.55 KB - PDF)
Qualification opinion ILSI / HESI submission of novel renal biomarkers for toxicity
The European Medicines Agency qualification process is a new, voluntary, scientific pathway leading to
either a CHMP opinion or a Scientific Advice on innovative methods or drug development tools. It
includes qualification of biomarkers developed by consortia, networks, public/private partnerships,
learned societies or pharmaceutical industry for a specific intended use in pharmaceuticals R&D.
English (EN) (1.25 MB - PDF)
Overview of comments on qualification opinion ILSI / HESI submission of novel renal biomarkers for toxicity
English (EN) (149.75 KB - PDF)
Consultation on qualification opinion ILSI / HESI submission of novel renal biomarkers for toxicity
The European Medicines Agency qualification process is a new, voluntary, scientific pathway leading to either a CHMP opinion or a Scientific Advice on innovative methods or drug development tools. It includes qualification of biomarkers developed by consortia, networks, public/private partnerships, learned societies or pharmaceutical industry for a specific intended use in pharmaceuticals R&D.
English (EN) (709.29 KB - PDF)
Final conclusions on the pilot joint European Medicines Agency / Food and Drug Administration VXDS experience on qualification of nephrotoxicity biomarkers
English (EN) (169.77 KB - PDF)
Letter of support for Measurable Residual Disease (MRD) as a Surrogate Efficacy Endpoint in Clinical Studies with Acute Myeloid Leukemia
English (EN) (164.51 KB - PDF)
Letter of support for Universal Immune System Simulator – Tuberculosis disease model (UISS-TB-DR)
English (EN) (107.66 KB - PDF)
Letter of Support for PRE score
English (EN) (191.69 KB - PDF)
Letter of support for a composite endpoint method for acceptability evaluation of oral drug formulations in the paediatric population
English (EN) (139.19 KB - PDF)
Letter of Support for World Federation of Hemophilia (WFH) Gene Therapy Registry (GTR)
English (EN) (338.11 KB - PDF)
Letter of Support for Forskolin-Induced Swelling (FIS) Assay: Biomarker for Cystic Fibrosis Transmembrane Conductance Regulator Protein (CFTR)
English (EN) (230.56 KB - PDF)
Letter of Support for TUMMY-UC – a Patient- and Observer-Reported Outcome for Paediatric Ulcerative Colitis (UC)
English (EN) (216.35 KB - PDF)
Letter of support for the development of the PAH-SYMPACT Instrument for use in Pulmonary Hypertension clinical trials
English (EN) (147.76 KB - PDF)
Letter of Support for the statistical adjustment on deep learning prognosis covariates obtained from histological slides
English (EN) (157.01 KB - PDF)
Letter of support for Minimal Disease Activity Score (MDA) as primary outcome instrument for clinical studies in psoriatic arthritis (PsA)
English (EN) (254.36 KB - PDF)
Letter of Support for an Acceptability Score Test in relative acceptability testing for oral medicines in children under 12 years of age
English (EN) (147.59 KB - PDF)
Letter of Support for Braintale platforms
English (EN) (138.68 KB - PDF)
Letter of Support of model-based clinical trial simulation platform (CTSP) for Duchenne Muscular Dystrophy
English (EN) (194.04 KB - PDF)
Letter of support for TREAT-NMD Core Dataset for Spinal Muscular Atrophy (SMA)
English (EN) (105.44 KB - PDF)
Letter of support for Neurofilament light in childhood neurological diseases
English (EN) (142.56 KB - PDF)
Letter of support for a Model-based Clinical Trial Simulation Platform to Optimize Design of Efficacy Evaluation Studies in Parkinson’s Disease
English (EN) (187.02 KB - PDF)
Letter of support for the Global Platform Study of Novel Medicines in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (Glo-BNHL platform)
English (EN) (376.19 KB - PDF)
Letter of support for Sjögren’s Tool for Assessing Response (STAR)
English (EN) (176.18 KB - PDF)
Letter of support for intermediate Age-Related Macular Degeneration (AMD) biomarker and novel clinical endpoint development
English (EN) (126.38 KB - PDF)
Letter of Support for performing registry-based post authorisation safety studies (PASS) in Multiple Sclerosis (MS) using data of the Big MS Data Network (BMSD)
English (EN) (143.32 KB - PDF)
Letter of support for Master Protocol for Type 1 diabetes prevention studies in INNODIA
English (EN) (188.65 KB - PDF)
Letter of support for International Niemann-Pick Disease Registry (INPDR)
English (EN) (102.32 KB - PDF)
Letter of support for Mobilise-D digital mobility outcomes as monitoring biomarkers - Follow-up
English (EN) (167.5 KB - PDF)
Letter of support for Mobilise-D digital mobility outcomes as monitoring biomarkers
English (EN) (127.95 KB - PDF)
Letter of support for N170 ERP as a prognostic biomarker for adaptive social functioning and its potential to stratify study populations in people with Autism spectrum disorders (ASD) without intellectual disability
English (EN) (185.49 KB - PDF)
Letter of support for the VABS-II Adaptive Behavior Composite (VABS-II-ABC) score as measure of adaptive social functioning in people with Autism Spectrum Disorders (ASD) without intellectual disability
English (EN) (182.88 KB - PDF)
Letter of support for drug-induced renal tubular injury biomarker(s)
On 12 August 2016 the Applicant Firalis SAS (on behalf of Safer and Faster Evidence-based Translation (SAFE-T) consortium) requested follow up qualification advice for novel biomarkers to assess DIKI pursuant to Article 57(1)(n) of Regulation (EC) 726/2004 of the European Parliament and of the Council. The procedure started during the SAWP meeting held on 30 August – 02 September 2016 and the advice was given in the framework of a joint EMA-FDA parallel advice procedure.
English (EN) (131.9 KB - PDF)
Letter of support for Islet autoantibodies as enrichment biomarkers for type 1 diabetes prevention studies, through a quantitative disease progression model
English (EN) (186.28 KB - PDF)
Letter of support for Corrected T1 (cT1)
English (EN) (124.38 KB - PDF)
Letter of support for Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF)
English (EN) (160.86 KB - PDF)
Retraction of the “Letter of support for drug -induced liver injury (DILI) biomarker” (EMA/423870/2016)
English (EN) (59.56 KB - PDF)
Letter of support for the development of Patient-Reported Outcomes tools for use as an endpoint in Inflammatory Bowel Disease (IBD) clinical trials
English (EN) (126.57 KB - PDF)
Letter of support for Model-based CT enrichment tool for CTs in aMCI
English (EN) (87.51 KB - PDF)
Letter of support for intermediate age related macular degeneration (AMD) biomarker and novel clinical endpoint development
English (EN) (129.15 KB - PDF)
Letter of support for the development of a needs-based quality of life Patient Reported Outcome (PRO) measure specific to adults with plexiform neurofibromas
On 1 March 2017 the Applicant Galen Research Ltd requested qualification opinion for a plexiform neurofibromas quality of life scale (the PlexiQoL), as biomarker for use as a secondary endpoint in clinical studies pursuant to Article 57(1)(n) of Regulation (EC) 726/2004 of the European Parliament and of the Council.
English (EN) (81.94 KB - PDF)
Letter of support for glutamate dehydrogenase, a biomarker of hepatocellular liver injury
English (EN) (80.97 KB - PDF)
Letter of support for drug-induced vascular injury (DIVI) biomarker
We are issuing this Letter of Support to SAFE”T and PSTC to encourage the further study of soluble biomarkers of endothelial cell injury and inflammation, and potential soluble markers of vascular smooth muscle cell injury, to monitor for drug”induced vascular injury (DIVI) in early clinical drug development.
English (EN) (171.82 KB - PDF)
Letter of support for molecular imaging of the dopamine transporter biomarker as an enrichment biomarker for clinical trials for early Parkinson's disease
English (EN) (79.84 KB - PDF)
Letter of support for Patient Data Platform for capturing patient-reported outcome measures for Dravet syndrome
On 09 December 2015 the applicant Dravet Syndrome Foundation Spain requested qualification opinion for Patient Data Platform as an electronic tool for capturing patient reported outcomes in paediatric epilepsies, pursuant to article 57(1)(n) of regulation (EC) 726/2004 of the European Parliament and of the Council.
English (EN) (79.73 KB - PDF)
Letter of support for reading speed and functional reading independence (FRI) index in geographic atrophy
On 16 February 2015 the applicant Roche Registration Ltd requested scientific advice for use of reading speed and functional reading independence (FRI) index pursuant to Article 57(1)(n) of regulation (EC) 726/2004 of the European Parliament and of the Council.
English (EN) (84.7 KB - PDF)
Letter of support for Leuven Postprandial Distress Scale (LPDS) as PRO in Postprandial Distress Syndrome (PDS)
English (EN) (72.61 KB - PDF)
Letter of support to explore EEG utility to measure deficits in social recognition in people with autism spectrum disorders (ASD) and its potential to stratify patient groups
On 14 September 2015 the Applicant EU-AIMS Consortium (IMI) requested follow-up qualification advice for methodology EEG to be used to stratify populations of people with Autism Spectrum Disorder (ASD) pursuant to Article 57(1)(n) of Regulation (EC) 726/2004 of the European Parliament and of the Council.
English (EN) (97.41 KB - PDF)
Letter of support to explore MRI methodology to be used to stratify populations of people with autism spectrum disorder (ASD)
On 14 September 2015 the Applicant EU-AIMS Consortium (IMI) requested follow-up qualification advice for MRI methodologies to be used to stratify populations of people with Autism Spectrum Disorder (ASD) pursuant to Article 57(1)(n) of Regulation (EC) 726/2004 of the European Parliament and of the Council.
English (EN) (82.87 KB - PDF)
Letter of support for eye tracking to be used to stratify populations of people with autism spectrum disorder (ASD)
On 14 September 2015 the Applicant EU-AIMS Consortium (IMI) requested follow-up qualification advice for Eye-tracking methodologies to be used to stratify populations of people with Autism Spectrum Disorder (ASD) pursuant to Article 57(1)(n) of Regulation (EC) 726/2004 of the European Parliament and of the Council.
English (EN) (98.87 KB - PDF)
Letter of support for measures of executive function and basic emotions to be used to stratify populations of people with autism spectrum disorder (ASD) and predict clinical outcome
On 14 September 2015 the Applicant EU-AIMS Consortium (IMI) requested follow-up qualification advice for measures of executive function and basic emotions to be used to stratify populations of people with Autism Spectrum Disorder (ASD) and predict clinical outcome pursuant to Article 57(1)(n) of Regulation (EC) 726/2004 of the European Parliament and of the Council.
English (EN) (86.97 KB - PDF)
Letter of support to explore clinical outcomes assessments utility to measure clinical symptoms in people with autism spectrum disorders (ASD)
On 14 September 2015 the Applicant EU-AIMS Consortium (IMI) requested follow-up qualification advice for Clinical Outcomes Assessments to measure clinical symptoms in people with Autism Spectrum Disorder (ASD) pursuant to Article 57(1)(n) of Regulation (EC) 726/2004 of the European Parliament and of the Council.
English (EN) (98.82 KB - PDF)
Letter of support for skeletal muscle injury biomarkers
English (EN) (77.24 KB - PDF)
Letter of support for micro-aneurysm formation rate (MAFR) biomarker
On 07 June 2013 the applicant Critical Health S.A. requested qualification of micro-aneurysm formation rate (MAFR) measured with a validated automated method, as an enrichment biomarker for studies of clinically significant macular oedema (CSMO) pursuant to Article 57(1)(n) of Regulation (EC) 726/2004 of the European Parliament and of the Council.
English (EN) (68.87 KB - PDF)
Letter of support for Predictive Safety Testing Consortium translational drug-induced kidney injury biomarkers
English (EN) (69.46 KB - PDF)